Pulmonary Edema Therapeutics Market Size to Grow by USD 339.45 million, High Prevalence of Risk Factors to Boost Market Growth – Technavio

[ad_2]

NEW YORK, Aug. 16, 2022 /PRNewswire/ — The “Pulmonary Edema Therapeutics Market by Type (Cardiogenic pulmonary edema and Non-cardiogenic pulmonary edema) and Geography (North America, Europe, Asia, and Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the pulmonary edema therapeutics market size between 2021 and 2026 is USD 339.45 mn. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report

Key Market Dynamics:

• Market Driver: The high prevalence of risk factors is driving the growth of the market. Pulmonary edema is a leading cause of death among adults living in developing countries. Heart failure is one of the most common causes of cardiogenic pulmonary edema, which is a condition wherein the left ventricle is unable to pump the adequate volume of blood required to meet the needs of the body. Pulmonary edema is one of the leading causes of death in adults living in developing countries. Lung diseases can be caused by individuals that have been exposed to chemicals during industrial accidents. Trauma as a result of accidents can also cause pulmonary edema. Thus, the high prevalence of risk factors is driving the growth of the global pulmonary edema market.
• Market Challenge: Adverse effects of available therapeutics are challenging the growth of the market. These effects include headache, fever, chills, nausea, and vomiting. For instance, DEMADEX is used for treating hypertension and edema caused by heart, liver, or kidney diseases. However, the common side effects of DEMADEX include sore throat, constipation, frequent urination, weakness, and others. Such adverse effects can hinder patient adherence to the treatment regimen, which will hamper the pulmonary edema therapeutics market growth during the forecast period.

Technavio provides key drivers, trends, and challenges to help businesses make

confident decisions. View our FREE PDF Sample Report right now!

Market Segmentation

The cardiogenic pulmonary edema segment will contribute the highest market share growth during the forecast period. The growth of this segment is mainly attributed to factors such as a high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension. Cardiogenic pulmonary edema is a result of increased pressure in the heart.

North America will be the leading region with 35% of the market’s growth during the forecast period. The US and Canada are the key countries for the pulmonary edema therapeutics market in North America. The growth of this region is attributed to factors such as the high prevalence of risk factors and increasing approval of drugs to treat pulmonary edema. Market growth in this region will be faster than the growth of the market in other regions.

Learn about the contribution of each segment summarized in concise infographics

and thorough descriptions. Buy Now to access exclusive information about the

segments

Some Companies Mentioned

• AbbVie Inc.
• ADVANZ PHARMA Corp.
• Apotex Inc.
• Bausch Health Companies Inc.
• CHIESI Farmaceutici SpA
• CMP Pharma Inc.
• Johnson and Johnson
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Validus Pharmaceuticals LLC

Want your report customized? Speak to an analyst and personalize your report

according to your needs.

Related Reports

Chronic Obstructive Pulmonary Disease Drugs Market by Product and Geography – Forecast

and Analysis 2021-2025

Browse Health Care Market Reports

Key Topics Covered:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis – Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 24: Chart on Type – Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type – Market share 2021-2026 (%)

• 5.2 Comparison by Type
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Cardiogenic pulmonary edema – Market size and forecast 2021-2026
• Exhibit 28: Chart on Cardiogenic pulmonary edema – Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Cardiogenic pulmonary edema – Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Cardiogenic pulmonary edema – Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Cardiogenic pulmonary edema – Year-over-year growth 2021-2026 (%)

• 5.4 Non-cardiogenic pulmonary edema – Market size and forecast 2021-2026
• Exhibit 32: Chart on Non-cardiogenic pulmonary edema – Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Non-cardiogenic pulmonary edema – Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Non-cardiogenic pulmonary edema – Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Non-cardiogenic pulmonary edema – Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America – Market size and forecast 2021-2026
• Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)

• 7.4 Europe – Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)

• 7.5 Asia – Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)

• 7.7 US – Market size and forecast 2021-2026
• Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)

• 7.8 Germany – Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany – Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany – Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany – Year-over-year growth 2021-2026 (%)

• 7.9 UK – Market size and forecast 2021-2026
• Exhibit 66: Chart on UK – Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on UK – Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on UK – Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on UK – Year-over-year growth 2021-2026 (%)

• 7.10 China – Market size and forecast 2021-2026
• Exhibit 70: Chart on China – Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on China – Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on China – Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on China – Year-over-year growth 2021-2026 (%)

• 7.11 Canada – Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada – Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada – Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada – Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AbbVie Inc.
• Exhibit 85: AbbVie Inc. – Overview
• Exhibit 86: AbbVie Inc. – Product / Service
• Exhibit 87: AbbVie Inc. – Key offerings

• 10.4 ADVANZ PHARMA Corp.
• Exhibit 88: ADVANZ PHARMA Corp. – Overview
• Exhibit 89: ADVANZ PHARMA Corp. – Business segments
• Exhibit 90: ADVANZ PHARMA Corp. – Key offerings
• Exhibit 91: ADVANZ PHARMA Corp. – Segment focus

• 10.5 Apotex Inc.
• Exhibit 92: Apotex Inc. – Overview
• Exhibit 93: Apotex Inc. – Product / Service
• Exhibit 94: Apotex Inc. – Key offerings

• 10.6 Bausch Health Companies Inc.
• Exhibit 95: Bausch Health Companies Inc. – Overview
• Exhibit 96: Bausch Health Companies Inc. – Business segments
• Exhibit 97: Bausch Health Companies Inc. – Key news
• Exhibit 98: Bausch Health Companies Inc. – Key offerings
• Exhibit 99: Bausch Health Companies Inc. – Segment focus

• 10.7 Johnson and Johnson
• Exhibit 100: Johnson and Johnson – Overview
• Exhibit 101: Johnson and Johnson – Business segments
• Exhibit 102: Johnson and Johnson – Key news
• Exhibit 103: Johnson and Johnson – Key offerings
• Exhibit 104: Johnson and Johnson – Segment focus

• 10.8 Lupin Ltd.
• Exhibit 105: Lupin Ltd. – Overview
• Exhibit 106: Lupin Ltd. – Product / Service
• Exhibit 107: Lupin Ltd. – Key news
• Exhibit 108: Lupin Ltd. – Key offerings

• 10.9 Novartis AG
• Exhibit 109: Novartis AG – Overview
• Exhibit 110: Novartis AG – Business segments
• Exhibit 111: Novartis AG – Key offerings
• Exhibit 112: Novartis AG – Segment focus

• 10.10 Pfizer Inc.
• Exhibit 113: Pfizer Inc. – Overview
• Exhibit 114: Pfizer Inc. – Product / Service
• Exhibit 115: Pfizer Inc. – Key news
• Exhibit 116: Pfizer Inc. – Key offerings

• 10.11 Sanofi
• Exhibit 117: Sanofi – Overview
• Exhibit 118: Sanofi – Business segments
• Exhibit 119: Sanofi – Key news
• Exhibit 120: Sanofi – Key offerings
• Exhibit 121: Sanofi – Segment focus

• 10.12 Teva Pharmaceutical Industries Ltd.
• Exhibit 122: Teva Pharmaceutical Industries Ltd. – Overview
• Exhibit 123: Teva Pharmaceutical Industries Ltd. – Business segments
• Exhibit 124: Teva Pharmaceutical Industries Ltd. – Key news
• Exhibit 125: Teva Pharmaceutical Industries Ltd. – Key offerings
• Exhibit 126: Teva Pharmaceutical Industries Ltd. – Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 127: Inclusions checklist
• Exhibit 128: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 129: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 130: Research methodology
• Exhibit 131: Validation techniques employed for market sizing
• Exhibit 132: Information sources

• 11.5 List of abbreviations
• Exhibit 133: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/pulmonary-edema-therapeutics-market-size-to-grow-by-usd-339-45-million-high-prevalence-of-risk-factors-to-boost-market-growth—-technavio-301604355.html

SOURCE Technavio

Source link
[ad_2]
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

[ad_2]